Skip to Content

Posts tagged with "Uncategorized"

  • Biological News

    The Landscape of Kinase Inhibitors

    I’ve been meaning to link to this article, which is the best overview I know of for kinase inhibitors. The authors (a large multicenter team led out of Munich) characterize 243 (!) kinase inhibitors that have made it into human trials across a very wide range of the known kinase enzymes, and the result is… Read More
  • Biological News

    Mistreating Enzymes For a Good Cause

    What happens when you chuck an active enzyme into the wrong solvent? Well, it stops working (or at the very least, it stops working as well as it did). And how do you know which one is the wrong solvent? Why, those are the ones that make it stop working. That round trip is to… Read More
  • In Silico

    Objections to (Some) Drug Discovery AI

    Here’s a piece to start some arguing: “AI in Drug Discovery is Overhyped”, by Mostapha Benhenda. I realize that a lot of people will read that title and go “Well, yeah, sure”, but it’s definitely worth seeing some specific examples (which the post has). Update: some of the authors involved have left detailed comm… Read More
  • Business and Markets

  • Chemical Biology

    Catching Up With Protein Degradation

    Just a short note today – I know that a lot of readers in the Northeast will be snowed out of work today anyway, but there are plenty of others who aren’t! I wanted to mention this short review on targeted protein degradation in J. Med. Chem. (a subject I last wrote about here). It’s… Read More
  • Alzheimer's Disease

    Alzheimer’s and the Rare Disease Model

    Politico is a good source for national political stories, but I don’t usually look to them for coverage of drug development. But they’ve done a good job with their recent “Pharma Issue”. One of the stories (by David Freedman) is on the difficulties of Alzheimer’s drug discovery, which are legendary. The contrast betwe… Read More
  • Cancer

    Bacteria and Cancer: Another Connection

    Three months ago, I wrote about a report that some kinds of pancreatic cancer seem to be associated with particular infections, and wondered “How many similar stories are out there that we don’t know about yet?” Well, that didn’t take long to start being answered. This recent paper in Science (from a multicenter team: Dana- Read More
  • Biological News

    Genetic Variation Gets More Real All the Time

    This study goes firmly into the file marked “You never could have done this one a few years ago, sonny”. We already know that there’s genetic variation in every population and in every individual. And we know that a large number of marketed drugs (about a third of them) target G-protein coupled receptors (GPCRs). But… Read More
  • Chemical News

    Hydrothermal Vents Weren’t Home?

    It’s probably not surprising, but you would be hard pressed to find an area that’s full of more intractable arguments than origin-of-life studies. There are so many theories, because it’s relatively easy to add new ones, and it’s difficult to impossible to put many of them to the real test. Meanwhile, the scientific stakes a… Read More
  • Business and Markets

    ‘Tis Unfortunately the Season

    Update: this post came just a few days before Teva announced that they’re starting a 14,000-job cutback, to run over the next two years. The season indeed. Unfortunately, the Thanksgiving-to-Christmas season is a traditional one in the drug industry for layoffs and site closures. This is especially true for larger companies, who time these th… Read More
...345...